Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome

Inoue, Teruo; Kato, Toru; Takayanagi, Kunio; Uchida, Toshihiko; Yaguchi, Isao; Kamishirado, Hirotoshi; Morooka, Shigenori; Yoshimoto, Nobuo

doi:10.1016/j.amjcard.2003.08.061

Cited by 42 publications

(32 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the increased MMP-9 levels appear to be emerging from the cardiac circulation as a significant aortic-coronary sinus gradient has been reported in patients undergoing catheterization and acute coronary syndromes (174). A similar pattern of increased release of MMP-3 from the coronary circulation has also been reported in patients with acute myocardial ischemia (175). While increased levels of specific MMP types have been reported early following myocardial ischemia, plasma TIMP levels do not follow the same pattern (164,186,485).…”

Section: Plasma Profiling Post-mimentioning

confidence: 67%

“…The first application of MMP/ TIMP plasma profiling was with acute coronary syndromes and MI (119, 164,174,175,186,187,253,264,411,459,461,476,485). For example, Kai et al (187) reported an early increase in plasma MMP-9 levels that were coincident in patients with acute coronary syndromes.…”

Section: Plasma Profiling Post-mimentioning

confidence: 99%

“…In addition, the release from the interstitial compartment may not be in a proportional manner to local interstitial levels or activity. This is particularly true for certain MMPs such as MMP-1 and MMP-13 in which very low or nondetectable levels may exist in the plasma (3,38,175,427,437,485,502), but abundant levels for these MMP types can be measured from myocardial samples. Thus plasma levels for MMPs and TIMPs may not be reflective of local tissue concentrations.…”

Section: Plasma Profiling: Limitationsmentioning

confidence: 99%

See 2 more Smart Citations

Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function

Spinale¹

2007

Physiological Reviews

1,008

1,023

View full text Add to dashboard Cite

It is now becoming apparent that dynamic changes occur within the interstitium that directly contribute to adverse myocardial remodeling following myocardial infarction (MI), with hypertensive heart disease and with intrinsic myocardial disease such as cardiomyopathy. Furthermore, a family of matrix proteases, the matrix metalloproteinases (MMPs) and the tissue inhibitors of MMPs (TIMPs), has been recognized to play an important role in matrix remodeling in these cardiac disease states. The purpose of this review is fivefold: 1) to examine and redefine the myocardial matrix as a critical and dynamic entity with respect to the remodeling process encountered with MI, hypertension, or cardiomyopathic disease; 2) present the remarkable progress that has been made with respect to MMP/TIMP biology and how it relates to myocardial matrix remodeling; 3) to evaluate critical translational/clinical studies that have provided a cause-effect relationship between alterations in MMP/TIMP regulation and myocardial matrix remodeling; 4) to provide a critical review and analysis of current diagnostic, prognostic, and pharmacological approaches that utilized our basic understanding of MMP/TIMPs in the context of cardiac disease; and 5) most importantly, to dispel the historical belief that the myocardial matrix is a passive structure and supplant this belief that the regulation of matrix protease pathways such as the MMPs and TIMPs will likely yield a new avenue of diagnostic and therapeutic strategies for myocardial remodeling and the progression to heart failure.

show abstract

Section: Plasma Profiling Post-mimentioning

confidence: 67%

Section: Plasma Profiling Post-mimentioning

confidence: 99%

Section: Plasma Profiling: Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function

Spinale¹

2007

Physiological Reviews

1,008

1,023

View full text Add to dashboard Cite

show abstract

“…These cells begin to release cytokines and super oxidases that activate metalloproteinases, including collagenases that affect the integrity of the plaque. Among the main metalloproteinases, which mediate this process of degradation, the MMP-1, 2, 3, 9, 12, and 13 have a relevant role, in conjunction with the matrix desintegrins and metalloproteinases (ADAM-1, ADAM-8, ADAM-15) and tissue inhibitors of matrix metalloproteinases (TIMP) 20 . The MMP expression and activation in atherosclerotic plaque promote the atherosclerotic process through plaque instability and platelet aggregation.…”

Section: The Action Of Metalloproteinases In Atherosclerotic Processesmentioning

confidence: 99%

The action of Metaloproteinases in the Atherosclerotic Diseases

2014

View full text Add to dashboard Cite

Cardiovascular diseases represent the main cause of morbidity and mortality in the world and are epidemic events involving the atherosclerosis and coronary artery disease in particular. There are a wide variety of factors and markers associated with the development and aggravation of these diseases, including atherosclerosis. Subclinical Atherosclerosis can be determined by serum inflammatory markers present in the atherogenic process. Such markers can take a direct or indirect indicator role on atherosclerotic cardiovascular disease. The extracellular matrix metalloproteinases are biomarkers closely related into modifying and remodeling of vascular wall and other tissues and can represent predictive value patterns to support diagnosis. This review discusses the function and types of matrix metalloproteinases and its use as an indicator of support for the diagnosis of atherosclerosis.Keywords: ischemia; plaque, atherosclerotic; peptide hydrolases; atherosclerosis. RESUMOAs doenças cardiovasculares compreendem a maior prevalência de morbidade e mortalidade no mundo, sendo uma epidemia da qual se destacam a aterosclerose e a doença arterial coronária. Há grande diversidade de fatores e marcadores associados ao desenvolvimento e agravo dessas doenças, incluindo a aterosclerose, que subclinicamente pode ser evidenciada pela determinação de marcadores inflamatórios séricos participantes do processo aterogênico. Tais biomarcadores são considerados medidas diretas ou indiretas de doença cardiovascular aterosclerótica. As metaloproteinases estão relacionadas com a modificação/remodelamento da parede vascular e outros tecidos, podendo representar parâmetros com valor preditivo para o apoio diagnóstico. Esta revisão aborda o mecanismo de ação e os tipos de metaloproteinases de matriz, bem como seu uso como indicador de apoio

show abstract

“…Both the MMP-1 and MMP-3 level correlated with the level of high-sensitivity CRP in ACS patients. 10 Kai et al demonstrated that peripheral blood levels of MMP-2 and MMP-9 were elevated in ACS patients relative to patients with chronic CAD or control subjects. 11 Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) is another promising biomarker of plaque vulnerability and/or rupture.…”

mentioning

confidence: 99%